patients with > 18 years old.

patients diagnosed with chronic hepatitis c in the presence of hcv rna in plasma that meet criteria for initiating antiviral therapy in routine clinical practice conditions.

patients genotype 1 and 4.

patients with the results of all the factors evaluable at the time of inclusion.

patients who have accepted their participation in the study through informed consent.

patients previously treated with interferon (ifn) and ribavirin (rbv).

patients with genotype 2, 3, 5 and 6.

patients with co-infection with hepatitis b.

patients with other liver diseases.

patients with any contraindications to the drugs used in the treatment of hepatitis